Therapeutic Peptide αCT1 Makes Surgical Scars Resemble Normal Unwounded Skin

Multi-level investigation combining: (1) Phase I clinical trial biopsies comparing αCT1 vs. vehicle-treated wounds within the same patient at 29 days; (2) animal model replication in Sprague-Dawley rats and IAF hairless guinea pigs; (3) in vitro scratch wound assays with NIH 3T3 mouse fibroblasts and primary human dermal fibroblasts; (4) agent-based computational modeling to predict collagen organization from fibroblast motility data.

Scarring is a major clinical problem affecting tens of millions of people annually after surgeries and injuries. Current scar treatments are largely limited to silicone sheets and steroid injections with modest efficacy. A peptide that fundamentally changes how collagen is deposited during healing — making scars structurally resemble normal skin — represents a mechanistically novel approach with demonstrated clinical benefit.

Connexin 43 is a gap junction protein found in many tissues. The discovery that a peptide mimicking its carboxyl terminus can modulate wound healing opened a new therapeutic area. αCT1 is notable because it has progressed from basic science through Phase II clinical trials — a rare achievement for a peptide-based wound healing therapeutic. The mechanistic insight that scar quality depends on fibroblast movement patterns, not just quantity, could inform broader wound healing research.

Phase I biopsies were taken at 29 days, which captures early scar remodeling but not the full maturation process. Clinical sample sizes were small. Animal models, while confirmatory, do not perfectly replicate human scarring biology. The computational model makes simplifying assumptions about fibroblast behavior. Long-term collagen remodeling dynamics were not fully characterized.